January 1, 2025Open Access

Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2− metastatic breast cancer in the US real-world setting

Key Points

Key points are not available for this paper at this time.

Abstract

This large real-world study suggested that there were no significant OS differences between 1L ribociclib, abemaciclib, and palbociclib in combination with an AI for patients with HR+/HER2- mBC. These findings together with other factors such as safety and quality of life are helpful in the selection of CDK4/6i combination therapy for patients with HR+/HER2- mBC.

Demander à l'IA

Bookmark

View Full Paper

Cite This Study

Rugo et al. (Wed,) studied this question.

synapsesocial.com/papers/69d8d9b0d2f7327e70ae46a0 https://doi.org/https://doi.org/10.1016/j.esmoop.2024.104103

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Demander à l'IA

Bookmark

View Full Paper